# AeroRx Therapeutics Inc.: Phase 2 study in COPD, Chronic Obstructive Pulmonary Disease (COPD) (64 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | AeroRx Therapeutics Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients |
| NCT ID | NCT07896252 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic; Lung Diseases, Obstructive |
| Intervention types | drug |
| Target enrollment | 64 |
| Site countries | United Kingdom |
| Posted | 2026-10-26 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07896252). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.